Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interaction Study of Azvudine and Rifampicin in Healthy Subjects
NCT07002255Phase 1Completed
- Sponsor
- Genuine Biotech
- Start
- Dec 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of azvudine in human immunodeficiency virus infection (HIV) and coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Genuine Biotech. Primary endpoints: Maximum Plasma Concentration at Steady State at Day 33, Time to Maximum Plasma Concentration at Steady State at Day 33 and 1 more. Started Dec 2021; status: completed.
02
Drugs
azvudine
03
Conditions
human immunodeficiency virus infection (HIV)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07002255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07002255.